Zoetis reports Q3 2026 lobbying on Farm Bill reauthorization, the PAW Act (H.R. 1842), and animal health trade. Explore full details on its key policy...

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Zoetis (ZTS) rated sell as growth slows and guidance falls. Read the latest analysis on the stock here.

Jefferies cut its target from USD 103 to USD 83 on October 20, 2026. Zoetis stock stood at EUR 70.35

The investment case for Zoetis Inc. (NYSE:ZTS) has changed significantly since declining demand in its U.S. companion-animal business has put pressure on earnings forecasts and affected the price of its shares. As a company in the animal health sector, Zoetis produces medicines, vaccines, and diagnostic products for both pets and livestock, and the wide range […]

Middle Coast Investing, an investment advisor firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. Market breadth in Q3 2026 reviews shows dominance by a few sectors, with S&P 500 stocks averaging a 9.7% return and only 40.55% above their 200-day moving average. Key themes include AI, inflation, and the U.S.-Iran conflict, […]